IL2 and breast carcinoma: Our data acquired in the cohort of healthy individuals may be also partially supported by the study of Payne et al. who demonstrated that ex vivo stimulation of peripheral blood mononuclear cells of breast cancer patients with bryostatin 1 and ionomycin combined with IL-2, IL-7, and IL-15 could expand and activate CD25+ NKT and NK cells as well as T memory cells that displayed enhanced reactivity against HER-2/neu positive breast cancer in the presence of myeloid-derived suppressor cells.